ALX Oncology Appoints Veteran Biopharma Leader Jeff Knight as Chief Development and Operating Officer
ALXO has more than doubled off its 52-week low of $0.404 on elevated volume (3.3× avg).
Summary
ALX Oncology appointed Jeff Knight, an experienced biopharmaceutical and oncology leader, as Chief Development and Operating Officer, a key hire for advancing its clinical pipeline.
Key Events · Executive and Board Changes · ALXO
-
New Chief Development and Operating Officer Appointed
Jeff Knight, with over 30 years of biopharmaceutical experience, including senior roles at Crinetics, Poseida, and Amgen, was appointed Chief Development and Operating Officer, effective April 13, 2026.
-
Significant Equity Incentive Granted
Mr. Knight will receive an annual base salary of $565,000, a 40% target cash bonus, and a stock option to purchase 800,000 shares, vesting over four years.
-
Strengthens Development and Operational Leadership
This strategic hire is critical for advancing ALX Oncology's evorpacept and ALX2004 clinical programs towards upcoming milestones, especially following recent corporate developments.
Analysis · ALXO · Life Sciences
This appointment is a significant positive for ALX Oncology, a clinical-stage biotechnology company. Jeff Knight brings over three decades of experience in clinical development, regulatory affairs, and operational execution, which is crucial as the company approaches key clinical milestones for its evorpacept and ALX2004 programs. Given the company's recent highly dilutive equity offering and the decision not to pursue U.S. regulatory approval for a prior lead candidate, strengthening the development and operational leadership is vital for successful execution and extending the cash runway through 1H 2028. The substantial stock option grant aligns Mr. Knight's incentives with long-term shareholder value.
At the time of this filing, ALXO was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $223.7M. The 52-week trading range was $0.40 to $2.66. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.